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Abstract
Alpha 1-proteinase inhibitor is a major serine proteinase inhibitor in the human cornea involved in the protection of the
avascular corneal tissue against proteolytic damage. This inhibitor is upregulated systemically during infection, inflamma-
tion and injury. Cytokines that mediate the acute phase response such as IL-1b and IL-2 increased a1-proteinase inhibitor
present in corneal organ culture media. This released inhibitor represented mainly newly synthesized protein. However,
IL-6, a general inducer of the acute phase response that upregulates a1-proteinase inhibitor in all other tissues and cells
tested, failed to alter corneal a1-proteinase inhibitor levels over the tested period of 24 h. In addition to IL-1b and IL-2,
a1-proteinase inhibitor levels in the corneal organ culture medium increased following the addition of FGF-2 and IGF-I.
The effect of the above growth factors and cytokines was relatively fast with maximal induction observed within the first 5
h. Among the tested growth factors and cytokines, IL-1b was the most potent and increased total corneal a1-proteinase
inhibitor levels approximately 2.4-fold in the cornea organ culture medium. Newly, synthesized a1-proteinase secreted into
the medium increased 3.9-fold. In addition to the effect on corneal a1-proteinase inhibitor, IL-1b also increased the
amount of a1-proteinase inhibitor released by monocytes and macrophages but not by HepG2, CaCo2, and MCF-7 cells
within 24 h. These results suggest that the cornea can locally control levels of a1-proteinase inhibitor in response to an
inflammatory insult. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
 .a1-Proteinase inhibitor a1-PI is a member of
the serpin family of proteins. It is the major pro-
teinase inhibitor in human plasma and many tissues
w x1 . Human a1-PI is a 59 kDa secretory glycoprotein
w xsynthesized mainly by the liver 2 . From the liver, it
is secreted into the blood stream and supplied to
tissues. Extrahepatic tissues and cells that synthesize
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this inhibitor include: blood monocytes and
w x w xmacrophages 3 , alveolar macrophages 4 , intestinal
w x w xepithelium cells 5 , breast carcinoma cells 6 and the
w xcornea 7 . Metabolic labeling and in situ hybridiza-
tion studies showed all three layers of the cornea
synthesize not only a1-PI, but also a1-anti-
w xchymotrypsin and a 2-macroglobulin 7–9 . The abil-
ity of the corneal cells to synthesize proteinase in-
hibitors is critical because of the avascular nature of
the cornea.
a1-PI is capable of inhibiting most serine pro-
teinases, however, the major target of this inhibitor is
w xneutrophil elastase 10 . This inhibitor plays an im-
portant role in protection of tissues against extensive
proteolytic damage. This is true during infection,
inflammation andror injury when proteolytic en-
zymes are released from the affected tissue and mi-
grating neutrophils. In response, a1-PI synthesis is
increased in hepatocytes and distributed to the tissues
w xvia the blood supply 11 .
During the acute phase response, levels of cy-
tokines such as IL-1b , IL-2 and IL-6 are increased
w x12,13 . However, these cytokines are not elevated
simultaneously; IL-1b and IL-2 are increased early
in the acute phase response and IL-6 is increased at
the end of the acute phase response. IL-6 upregulates
the synthesis of a1-PI in most tissues and cells that
w xsynthesize this inhibitor 14 . In contrast, IL-1b in-
w xcreases a1-PI in MCF-7 breast 6 but does not affect
w xa1-PI levels in HepG2 cells 15 . The effects of
cytokines and growth factors on corneal proteinase
inhibitors was not previously studied. The only known
molecule reported to increase levels of a1-PI in the
w xcornea was retinol 16 . In this study, we showed that
in the cornea a1-PI levels were increased following
the addition of IL-1b and IL-2 but not IL-6. In
addition, corneal a1-PI levels were also increased in
the presence of FGF-2 and IGF-I.
2. Materials and methods
2.1. Materials
Interleukin-6 was purchased from Genzyme Cam-
.bridge, MA . FGF-2, EGF, IGF-I, TGF-a , TNF-a ,
 .IL-1b , and IL-2 were from Promega Madison, WI .
Culture medium, penicillin–streptomycin and fetal
calf serum were from Life Technologies Gaiters-
.burg, MD . All other chemicals used were from
w35 x  .Sigma S methionine labeling grade was from
 .Amersham Arlington Heights, IL .
2.2. Methods
2.2.1. Cornea organ culture
Human eyes in humid chambers were obtained
from the Wisconsin Lions Eye Bank Milwaukee,
.WI kept at 48C until used. The corneas were dis-
sected from the globe within 18–36 h of death of the
donor. The levels of a1-proteinase inhibitor in the
organ cultured corneas or the culture mediums was
not dependent on the elapsed time between death of
the donor and placement in culture. The corneas were
weighed and placed in 1 ml of minimum essential
medium containing 100 U penicillin and 100 mg
streptomycin and cultured for 2 h, at 378C with 5%
CO . After a 2-h preincubation period growth factors2
or cytokines were added and culture continued for an
additional 2, 5, 15 or 24 h. The following growth
factors and cytokines were used: basic fibroblast
 .growth factor FGF-2 , epidermal growth factor
 .  .EGF , insulin-like growth factor-I IGF-I , tumor
 .necrosis factor-a TNF-a , transforming growth fac-
 .  .tor-a TGF-a , interleukin-1b IL-1b , interleukin-2
 .  .IL-2 , and interleukin-6 IL-6 . All growth factor
and cytokines were used at 5 ngrml as the final
concentration except for TNF-a which was used at
the final concentration of 0.2 ngrml. These levels
were chosen based on the reported active levels of
the cytokinesrgrowth factors in vitro as specified by
the supplier and are within the range of concentra-
tions observed for the cytokines and growth factors
found in the tears, aqueous humor or the cornea
w xfollowing injury 17–21 . TNF-a was used at 0.2 ng
because of its lower concentration in wounded corneas
w x 20 . Control corneas contralateral to the experimen-
.tal corneas were incubated in the same manner
except the growth factors and cytokines were not
w35 x  .added. In addition, S methionine 83 mCirml was
added to some FGF-2 and IL-1b treated and control
corneal cultures to determine whether a1-PI mea-
sured by immunological methods represented newly
synthesized inhibitor. At 0, 2, 5, 15 and 24 h time
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points, the corneas were removed from the medium,
washed in phosphate-buffered saline, frozen in liquid
nitrogen and freeze fractured. Freeze fractured corneas
were homogenized with a glass homogenizer and
extracted in 10 mM Tris–Cl buffer, pH 7.2, 140 mM
NaCl, 10 mM EDTA, 5 mM E64, 1 mM pepstatin,
 .10 mM phenylmethylsulfonyl fluoride PMSF , 1%
sodium deoxycholate, 0.1% sodium dodecyl sulfate
 . SDS and 1% nonidet NP40 100 ml per 10 mg
.corneal tissue . The particulate matter was removed
by centrifugation at 15 000=g for 15 min at 48C.
2.2.2. Cell culture
The human liver tumor cell line HepG2 and the
human breast adenocarcinoma cell line MCF-7 were
purchased from American Type Culture Collection
 .ATCC, Rockville, MD . Both cell lines were cul-
tured in the minimum essential medium supple-
mented with 10% fetal calf serum according to the
ATCC recommended protocol. The human intestinal
epithelial cell line, CaCo2, was obtained from Dr.
 .Nancy Dahms Medical College of Wisconsin and
cultured in Dulbecco’s modified Eagle medium sup-
plemented with 20% fetal calf serum. ‘Buffy coat’
fractions of the human blood were provided by the
Blood Center of Southeastern Wisconsin. Leukocytes
were isolated from the ‘buffy coat’ by the method of
w xCarlson and Kaneko 22 . Isolated leukocytes were
cultured in the Medium 199 containing 100 U of
penicillin and 100 mg streptomycin according to a
w xpreviously described method 23 . Mononuclear cells
 .were used either after 2 h in culture monocytes or
 .after 7 days macrophages . Cells were preincubated
in the minimum essential medium without serum for
2 h and then in the presence or absence of 5 ngrml
IL-1b for additional 5 h. The conditioned medium
was collected. Cells were harvested by trypsinization,
centrifuged and extracted in the same buffer and by
the same procedure used for corneal extraction.
2.2.3. Immunoassay for a1-PI
Quantification of a1-PI by immunoprecipitation
w xwas done as previously described 7 . Briefly, the
assay was conducted in 96-well Durapore membrane
 .plates Millipore; Bedford, MA . First, human a1-PI
 .Athens Research Technologies; Athens, GA was
bound to the membranes at the bottom of the plate
wells by the incubation of 10 mgrwell of a1-PI in
100 ml of 50 mM Tris buffer, pH 7.5 containing 150
 .mM NaCl and 0.02% sodium azide buffer A for 1.5
h at room temperature. Nonbound sites on the mem-
brane were blocked using 5 mg bovine serum albu-
minrwell in 200 ml buffer A. The membranes were
washed once with 200 mlrml buffer A and then
three times with 200 mlrwell of the same buffer
containing 0.05% Triton X-100. Next, the mem-
branes were incubated for 1 h with 5.11 mg mouse
monoclonal antibodiesrwell to human a1-PI Medix
.Biotech; Foster City, CA in 200 ml buffer A. The
membranes were washed as before. One hundred
mlrwell of corneal extract, conditioned medium, or
standard a1-PI solutions was added to the wells and
incubated for 2 h at room temperature. Immunopre-
cipitated proteins were released from the membrane
by incubation with 100 ml of 0.1 M Tris, pH 6.8,
20% glycerol, 4% SDS, 26.7 mM dithiothreitol and
0.05% bromphenol blue for 10 min at 908C. Proteins
were then separated by 10% SDS-PAGE under reduc-
w xing conditions 24 and either visualized by silver
 .staining BioRad; Hercules, CA or when
w35 xS methionine labeled, processed for autoradiog-
raphy. For autoradiography, the gels were incubated
 .in Amplify Amersham, Artlington Heights, IL for 2
h, dried and exposed to X-Ray film. The bands on the
gels or the X-ray film were digitized using AMBIS
 .imaging system San Diego, CA . The concentration
of a1-PI was determined from the standard curve
and expressed as a percent of the amount of a1-PI in
control corneas.
2.2.4. Western blot assay
The cornearcell extracts or conditioned mediums
were mixed with an equal volume of 0.1 M Tris
buffer pH 6.8, 20% glycerol, 2% SDS, 0.004%
bromphenol blue and electrophoresed on 9% SDS-
w xpolyacrylamide gels 24 . Following electrophoresis,
the proteins were electroblotted to nitrocellulose
 .sheets BA83-Schleicher and Schuell; Keene, NH .
The nitrocellulose blots were then blocked with 50
ml 10% dry milk in TBS-T buffer pH 7.6 3.5 mM
.Tris, 137 mM NaCl, 0.1% Tween-20 . The blots were
washed, probed and the bands visualized by chemilu-
minescence according to the protocol recommended
for use with the enhanced chemiluminescence detec-
tion system ECL, Amersham; Arlington Heights,
.IL . Monoclonal antibodies raised against human a1-
( )G. Bosko˝ic, S.S. TwiningrBiochimica et Biophysica Acta 1403 1998 37–46ˇ ´40
 .PI Medix Biotech , human a1-antichymotrypsin
 .  .Medix Biotech , human b-actin Sigma and rabbit
glyceraldehyde-3-phosphate dehydrogenase
 . GAPDH Advanced Immuno Chemical, Long
.Beach, CA were used as primary antibodies.
Horseradish peroxidase conjugated-goat anti-mouse
 .IgG BioRad; Hercules, CA was used for the sec-
ondary antibody. The intensities of the protein chemi-
luminescent bands were measured on an AMBIS
 .imaging system San Diego, CA and the amount of
the proteins determined from the standard curves.
 .Human a1-PI Athens Research Technologies , a1-
 .antichymotrypsin Athens Research Technologies
 .and GAPDH Worthington Biochemical were used
to prepare standard curves.
2.2.5. Dot blot assay
Dot blot assays were done by loading cornealrcell
extracts or conditioned medium onto nitrocellulose
 .sheets BA83-Schleicher and Schuell in a 96-well
 .Mini-fold dot blot apparatus Schleicher and Schuell .
The dot blots were washed and probed as described
for the Western blots. The intensities of the dot blots
were quantified using an EL380 Microplate Autore-
 .ader Bio-Tek Instruments; Winooski, VT .
2.2.6. Statistical analysis
The a1-PI levels obtained by immunoprecipita-
tion, Western blot assay and dot blot assay were
statistically analyzed by the Student’s t-test using
 .SigmaStat software Jandel .
 .Fig. 1. The effect of growth factors on a1-PI protein levels in the cornea. Levels of a1-PI retained in the cornea a and secreted into the
 .  .  .  .  .  . w35 xmedium b following the addition of EGF \ , FGF-2 ‘ , IGF-I e , TGF-a I , and TNF-a ^ , or FGF-2 plus S methionine
 .octagon as determined by immunoprecipitation. Growth factors were added to the culture medium at a final concentration of 5 ngrml,
except TNF-a which was added to final concentration of 0.2 ngrml. Levels of a1-PI in the treated corneas are expressed as percent of
the levels of a1-PI in the untreated corneas. All experimental values represent the average of at least three independent measurements in
corneas from at least three individuals. The error bars represent the absolute error. Inset: Representative electrophoretic separation of
immunoprecipitated 35S methionine labeled a1-PI synthesized by human corneas in the presence or absence of 5 ngrml FGF-2. The
 .bands were visualized by autoradiography. ))Experimental values significantly different from control value p-0.001 . )Experimental
 .values significantly different from control value p-0.005 .
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3. Results
3.1. Effect of growth factors on corneal a1-PI
The effects of growth factors FGF-2, EGF, IGF-I,
.TNF-a , and TGF-a on a1-PI levels in the corneal
tissue and conditioned medium were analyzed by
 .time course experiments Fig. 1 . Following a 2-h
preincubation in serum-free minimal essential
medium, the above mentioned growth factors were
added to the culture medium and the amounts of
a1-PI protein were determined immunologically at 2,
5, 15, and 24 h following their addition. None of the
tested growth factors were able to significantly alter
a1-PI protein levels retained in the corneal tissue
 .Fig. 1a . However, FGF-2 and IGF-I increased a1-PI
protein levels secreted into the conditioned medium
 .over that secreted by the control corneas Fig. 1b . A
2-fold increase in secreted a1-PI was observed 2 h
following addition of FGF-2 to the cultured medium.
At subsequent time points, 5, 15 and 24 h, a1-PI
levels were also significantly higher than control
levels. IGF-I increased a1-proteinase levels 1.4-fold
at 5 h after the addition of the growth factor but not
at 2, 15 or 24 h. EGF, TGF-a , and TNF-a did not
affect a1-PI levels.
In the control corneas incubated for the same
period of time but without growth factors or cy-
.tokines , the levels of a1-PI secreted into the condi-
tioned medium were approximately 4-fold higher
 .Fig. 2. The effect of cytokines on a1-PI protein levels in the cornea. Levels of a1-PI retained in the cornea a and secreted into the
 .  .  .  . 35  .conditioned medium b following addition of IL-1b ‘ , IL-2 \ , and IL-6 I , or IL-1b plus S-methionine e as determined by
immunoprecipitation. Cytokines were added to the culture medium at a final concentration of 5 ngrml. Levels of a1-PI in the treated
corneas are expressed as percent of the levels of a1-PI in the untreated corneas. All experimental values represent the average of at least
three independent measurements on corneas from at least three individuals. The error bars represent the absolute error. Inset:
w35 xElectrophoretic separation of immunoprecipitated S methionine labeled a1-PI synthesized by human corneas in the presence or
absence of 5 ngrml IL-1b. The bands were visualized by autoradiography. ))Experimental values significantly different from control
 .  .value p-0.001 . )Experimental values significantly different from control value p-0.005 .
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compared to the a1-PI amounts retained in the cornea
tissue 0.19q0.01 mgrmg cornea for the corneal
tissue and 0.87q0.2 mgrmg cornea for the condi-
.tioned medium at 5 h. Upon stimulation with FGF-2
for 2 h, the amount of a1-PI released into the
medium increased to approximately 11-fold that pre-
sent in the cornea 0.14q0.02 mgrmg cornea for
the corneal tissue and 1.52q0.3 mgrmg cornea for
.the conditioned medium . A more modest increase
was noted for IGF-I 0.21q0.02 mgrmg cornea for
the corneal tissue and 1.08q0.0 mgrmg cornea for
.the conditioned medium .
To determine whether the increase in a1-PI se-
creted into the cornea conditioned medium in the
presence of growth factors represented the stimula-
tion of new protein synthesis, selected corneas were
metabolically labeled with 35S-methionine in the
presence or absence of FGF-2. After the initial 2 h
preincubation period, the label was added at the same
time as the growth factor. Very little labeled a1-PI
was immunoprecipitated after 2 h in the control Fig.
.1b . The amount of labeled a1-PI immunoprecipi-
tated differed from one donor to another Fig. 1b and
.Fig. 2b, insets . Because the contralateral cornea was
used for the treated corneas, the percent increase due
to a given treatment was similar at the various time
points between donors. Metabolically-labeled a1-PI
concentrations in the conditioned mediums of corneas
treated with FGF-2 were increased approximately
2-fold at 5, 15 and 24 h over those in the control
Fig. 3. The effect of IL-1b on a1-PI, a1-antichymotrypsin and b-actin protein levels in the cornea and cells derived from the tissues
 .  .  .that synthesize a1-PI. Protein levels of a1-PI I , a1-antichymotrypsin B , and b-actin square with horizontal lines in the cornea
 .  .and cell extract a and conditioned medium b following 5 h incubation in the presence of 5 ngrml IL-1b. Values were determined by
dot blot assay except for b-actin which was determined by Western blot assay. Levels of measured proteins were standardized based on
GAPDH levels. All experimental values represent the average of at least three independent measurements. The error bars represent the
 .absolute error. ))Experimental values significantly different from control value p-0.001 .
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conditioned mediums. This increase is similar to that
observed for the secreted protein levels in the pres-
ence of FGF-2.
3.2. Effect of cytokines on corneal a1-PI
Similar to the effect of the growth factors, no
cytokine tested had a significant effect on a1-PI
 .protein levels in the corneal tissue Fig. 2a , however,
two cytokines increased secretion of a1-PI into the
conditioned medium. IL-1b and IL-2 were able to
elevate a1-PI protein levels secreted into the condi-
 .tioned medium Fig. 2b . In the presence of IL-1b ,
a1-PI levels were increased 2.4-fold over the control
level, while addition of IL-2 to the culture medium
induced an 1.8-fold increase. The maximal increase
in a1-PI levels was observed at 5 h following addi-
tion of either IL-1b or IL-2. IL-6 did not signifi-
cantly alter corneal a1-PI levels in corneal tissue or
corneal conditioned medium over the tested period of
24 h.
Corneas incubated in organ culture with IL-1b
w35 xand metabolically labeled with S methionine se-
creted 3.9-, 3-and 2-fold more a1-PI at 5, 15 and 24
h, respectively, over those in the control culture Fig.
.2b . At 2 h, metabolically labeled a1-PI was ob-
served in the conditioned medium of corneas incu-
bated with IL-1b but very little was detected in the
control conditioned medium. With time, the newly
synthesized a1-PI present in the conditioned medium
of the control corneas increased faster than in the
IL-1b treated corneas resulting in a decrease in the
fold stimulation with the cytokine.
3.3. Effect of IL-1b on a1-PI in cells that synthesize
this inhibitor
As shown in Fig. 2, IL-1b increased a1-PI levels
in corneal conditioned medium. Furthermore, among
the growth factors and cytokines tested, IL-1b had
the greatest effect on a1-PI protein levels in the
cornea. The effect of this cytokine on corneal a1-PI
levels was compared to the effect of IL-1b on this
inhibitor in other cells that synthesize a1-PI. a1-PI
levels were determined 5 h following the addition of
IL-1b to the corneal, HepG2, CaCo2, MCF-7, blood
 .monocyte, and blood macrophage cultures Fig. 3 . In
addition to the cornea, IL-1b significantly increased
a1-PI levels secreted into monocyte and macrophage
conditioned mediums, 1.7- and 1.9-fold, respectively
 .Fig. 3b . After 5 h of culture, IL-1b did not affect
a1-PI levels in HepG2, CaCo 2, and MCF-7 cells.
This cytokine did not alter the levels of a1-PI re-
 .tained in cells Fig. 3a . IL-1b had no significant
effect on the levels of a1-antichymotrypsin or b-actin
 .in the cornea or any cells tested Fig. 3a and b .
4. Discussion
FGF-2, IGF-I, IL-1b , and IL-2 increased the se-
cretion of a1-PI from human corneas in organ cul-
ture relative to nontreated control corneas. The in-
crease in secreted a1-PI represents newly synthe-
w35 xsized protein. S methionine labeled a1-PI levels
increased in response to IL-1b or FGF-2 relative to
control levels in a similar manner to that observed for
secreted unlabeled a1-PI. The IL-1b and FGF-2
stimulated increase in metabolic labeled a1-PI repre-
sented the a1-PI synthesized after the addition of the
cytokine or growth factor. In the nonlabeled experi-
ments, a1-PI synthesized and secreted during the 2 h
preincubation period was measured in addition to the
inhibitor synthesized following the addition of the
cytokines or growth factors. Considering this differ-
ence, the measured cytokine and growth factor stimu-
lations by both methods are in very good agreement.
In contrast to the a1-PI levels in the corneal
conditioned medium, the a1-PI level in the cornea
did not increase in response to the cytokines. Because
a1-PI is a secreted protein, these results suggest the
corneal epithelial andror endothelial cells are af-
fected by the cytokinesrgrowth factors to a greater
extent than the stromal keratocytes. If stromal kerato-
cyte synthesis of a1-PI was stimulated, an increase
in a1-PI would be expected in the cornea due to
deposition of this inhibitor in the stromal extracellu-
lar matrix. Corneal stromal keratocytes can synthe-
size a1-PI as shown by the presence of a1-PI
mRNA in these cells by in situ hybridization studies
w xand metabolically labeled a1-PI in the stroma 7 .
Thus, the lack of an effect on the retained levels of
 .a1-PI may 1 reflect an absence of receptors to the
 .cytokines and growth factors on the stromal cells, 2
decreased access of the cytokines to the stromal
keratocytes relative to the epithelial and endothelial
 .cells or 3 a difference in the mechanism of regula-
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tion of a1-PI synthesis by the stromal cells. Because
IL-1R and FGF-R are present on stromal keratocytes
w x25 , the absence of a response to the cytokines by
stromal keratocytes probably is not due to a lack of
 .receptors. Diffusion of the cytokines 7 to 26 kDa
into the stromal matrix may be a factor. Unlike
growth factors and cytokines, a smaller molecule,
retinol induces increases in the a1-PI retained in the
w xcornea 16 . In addition, there may also be a differ-
ence in the mechanism of control of the synthesis of
a1-PI in the corneal stromal keratocytes relative to
the epithelial andror endothelial cells.
In the presence of IGF-I, IL-1b and IL-2, a1-PI
levels in the cornea conditioned medium peaked at 2
to 5 h relative to the controls and then decreased.
This decrease in a1-PI concentration in the presence
of the cytokinesrgrowth factors relative to control
a1-PI at the later time points was probably due to
increased degradation of a1-PI. IL-1b , like IL-1a ,
stimulates the synthesis of matrix metalloproteinases
w x  .26 and plasminogen unpublished results by the
cornea.
Among the tested growth factors and cytokines,
IL-1b , an acute phase cytokine, increased a1-PI
levels the most. In addition to the cornea, IL-1b
increased a1-PI levels in the blood monocyte and
macrophage conditioned mediums but not the HepG2,
CaCo2, or MCF-7 cell conditioned mediums. A pre-
vious study also showed this cytokine did not affect
w xa1-PI levels in HepG2 cells 27 . Following 54 h
incubation, IL-1b treatment upregulated a1-PI in
w xMCF-7 cells 6 . In our study, a1-PI levels in cells
and cornea were determined following a 5-h incuba-
tion in the presence of IL-1b. Lack of a response of
a1-PI to IL-1b by HepG2 and CaCo2 cells was not
due to a deficiency of the IL-1 receptor because these
w xcells contain the IL-1R 28,29 . Further, other genes
w xrespond to IL-1b in these cells 28–33 .
In contrast to IL-1b , IL-6, a general inducer of the
acute phase response, did not alter corneal a1-PI
levels during the tested period of 24 h. This was true
both for 5 ngrml used in the current experiments and
w xat 100 ngrml in our previous experiments 16 . IL-6
at 100 ngrml was able to increase a1-PI levels
secreted into the conditioned mediums by HepG2,
CaCo2, MCF-7 cells, blood monocytes and
w xmacrophages but not cornea 16 . The absence of a
response by the cornea is not due to a lack of IL-6
receptors. Corneal epithelial cells can respond to IL-6
w xto upregulate the synthesis of integrin a5b 33 . The
absence of a response of a1-PI to IL-6 in the cornea
is probably due to differences in the regulation of the
a1-PI gene by IL-6 between tissues.
The observed cytokinergrowth factor stimulated
secretion of a1-PI may be physiologically important
since these cytokinesrgrowth factors are locally
available to the cornea either under normal or disease
conditions and are available in the same concentra-
tion ranges as those used in the current experiments
w x17–21 . FGF-2, IGF-I, IL-1b , and IL-2 are synthe-
w xsized by corneal cells 17,25,34–36 and are benefi-
w xcial in corneal wound healing 37,38 . In organ cul-
ture of human corneas, FGF-2 promotes endothelial
wound healing predominately by stimulation of cell
w xmigration 38 . In the closed wound, the central en-
dothelial cell density is significantly higher in FGF-2
treated corneas than in controls. The time of complete
wound closure is also shortened. After excimer laser
keratomileusis in a rabbit model, a highly significant
acceleration in epithelial wound healing is observed
following FGF-2 application to the corneal surface
w x37 . IL-1b increases the rate of closure of wounds
w xinflicted on rabbit corneal epithelial cell cultures 39 .
IL-2 also increases corneal wound healing but, the
effect is indirect because IL-2 increases FGF-2 ex-
w xpression in the cornea 40 . The increase in corneal
wound healing in the presence of FGF-2, IL-1b and
IL-2 can, at least in part, be explained by upregula-
tion of corneal a1-PI in the presence of these extra-
cellular molecules.
The ability of the cornea to increase the synthesis
of a1-PI in response to cytokines and growth factors
indicates that the cornea can respond to its environ-
ment. Corneal synthesis of this inhibitor is probably
important under inflammatory conditions to protect
the cornea from degradation by neutrophil elastase.
The avascular nature of the cornea makes this re-
sponse critical because of the lack of supply of a1-PI
from blood.
Acknowledgements
This work is supported in part by grants EY-06663
and P30 EY-01931 from the National Eye
InstituterNational Institute of Health.
( )G. Bosko˝ic, S.S. TwiningrBiochimica et Biophysica Acta 1403 1998 37–46ˇ ´ 45
References
w x1 J. Travis, G.S. Salvenson, Human plasma proteinase in-
 .hibitors, Annu. Rev. Biochem. 52 1983 655–709.
w x2 J.-F. Mornex, A. Chytil-Weir, Y. Martinet, M. Courtney,
J.-P. LeCocq, R.G. Crystal, Expression of the alpha-1-anti-
trypsin gene in mononuclear phagocytes of normal and
a-1-antitrypsin deficient individuals, J. Clin. Invest. 77
 .1986 1952–1961.
w x3 D.H. Perlmutter, F.S. Cole, P. Kilbridge, T.H. Rossing, H.R.
Colten, Expression of the a -proteinase inhibitor gene in1
human monocytes and macrophages, Proc. Natl. Acad. Sci.
 .U.S.A. 82 1985 795–799.
w x4 R. White, D. Lee, G.S. Habicht, A. Janoff, Secretion of
a1-proteinase inhibitor by cultured rat alveolar macrophages,
 .Am. Rev. Respir. Dis. 123 1981 447–449.
w x5 E.P. Molmenti, T. Ziambaras, D.H. Perlmutter, Evidence for
an acute phase response in human intestinal epithelial cells,
 .J. Biol. Chem. 268 1993 14116–14124.
w x6 T.H. Finlay, S. Tamir, S.S. Kadner, M.R. Cruz, J. Yavelow,
 .M. Levitz, a 1 -Antitrypsin-independent and anchorage-in-
dependent growth of MCF-7 breast cancer cells, Endocrinol-
 .ogy 133 1993 996–1002.
w x7 S.S. Twining, T. Fukuchi, B.Y.J.T. Yue, P.M. Wilson, G.
Boskovic, Corneal synthesis of a1-proteinase inhibitor
 .  .a1-antitrypsin , Invest. Ophthalmol. Vis. Sci. 35 1994
458–462.
w x8 S.S. Twining, T. Fukuchi, B.Y.J.T. Yue, P.M. Wilson, X.
Zhou, G. Loushin, a 2-Macroglobulin, is present in and
synthesized by the cornea, Invest. Ophthalmol. Vis. Sci. 35
 .1994 3226–3233.
w x9 S.S. Twining, T. Fukuchi, B.Y.J.T. Yue, P.M. Wilson, X.
Zhou, a1-Antichymotrypsin is present in and synthesized
 .by the cornea, Curr. Eye Res. 13 1994 433–439.
w x10 K. Beatty, J. Bieth, J. Travis, Kinetics of association of
serine proteinases with native and oxidized a-1-proteinase
inhibitor and a-1-antichymotrypsin, J. Biol. Chem. 255
 .1980 3931–3934.
w x11 A. Koj, D. Magielska-Zero, A. Kurdowska, J. Bereta, Pro-
teinase inhibitors as acute phase reactants: regulation of
 .synthesis and turnover, Adv. Exp. Med. Biol. 240 1988
171–181.
w x12 J. Saklatvala, Intracellular signaling mechanism of inter-
leukin 1 and tumour necrosis factor: possible targets for
 .therapy, Br. Med. Bull. 61 1995 402–418.
w x13 R.J. Stewart, P.A. Marsden, Biologic control of the tumor
necrosis factor and interleukin-1 signaling cascade, Am. J.
 .Kidney Dis. 25 1997 954–966.
w x14 D.H. Perlmutter, L.T. May, P.B. Sehgal, Interferon b 2rin-
terleukin 6 modulates synthesis of a1-antitrypsin in human
mononuclear phagocytes and in human hepatoma cells, J.
 .Clin. Invest. 84 1989 138–144.
w x15 A. Koj, E. Korzus, H. Baumann, T. Nakamura, J. Travis,
Regulation of synthesis of some proteinase inhibitors in
human hepatoma cells HepG2 by cytokines, hepatocyte
growth factor and retinoic acid, Biol. Chem. Hoppe-Seyler
 .374 1993 193–201.
w x16 G. Boskovic, S.S. Twining, Retinol and retinaldehyde
specifically increase a1-proteinase inhibitor in the human
 .cornea, Biochem. J. 322 1997 751–756.
w x17 J. Becker, S. Salla, U. Dohmen, C. Redbrake, M. Reim,
Explorative study of interleukin levels in the human cornea,
 .Grafes Arch. Clin. Exp. Ophthalmol. 233 1994 766–771.
w x18 J.A. Hobden, S.A. Masinick, R.P. Barrett, L.D. Hazlett,
Proinflammatory cytokine deficiency and pathogenesis of
Pseudomonas aeruginosa keratitis in aged mice, Infect.
 .Immun. 65 1997 2754–2758.
w x19 F. Malecaze, V. Simorre, P. Chollet, J.L. Tack, M. Muraine,
D. Leguellec, N. Vita, J.L. Arne, J.M. Darbon, Interleukin-6
in tear fluid after photorefractive keratectomy and its effects
 .on keratocytes in culture, Cornea 16 1997 580–587.
w x20 M. Vesaluoma, A.M. Teppo, C. Gronhagen-Riska, T. Tervo,
Increased release of tumour necrosis factor-a in human tear
fluid after excimer laser induced corneal wound, Br. J.
 .Ophthalmol. 81 1997 145–149.
w x21 D.R. Arnold, P. Moshayedi, T.J. Schoen, B.E. Jones, G.J.
Chader, R.J. Waldbillig, Distribution of IGF-I and -II, IGF
 .binding proteins IGFBP and IGFBP mRNA in ocular
fluids and tissues: potential sites of synthesis of IGFBPs in
 .aqueous and vitreous, Exp. Eye Res. 56 1993 555–565.
w x22 G.P. Carlson, J.J. Kaneko, Isolation of leukocytes from
bovine peripheral blood, Proc. Soc. Exp. Biol. Med. 142
 .1997 853–856.
w x23 L.P. Einstein, E.E. Schneeberger, H.R. Colten, Synthesis of
the second component of complement by long-term primary
 .cultures of human monocytes, J. Exp. Med. 143 1976
114–126.
w x24 U.K. Laemmli, Cleavage of structural proteins during the
assembly of the head of bacteriophage T4, Nature 227
 .1970 680–685.
w x25 D.Q. Li, S. Tseng, Three patterns of cytokine expression
potentially involved in epithelial–fibroblast interactions of
 .human ocular surface, Exp. Eye Res. 63 1994 71–79.
w x26 M.E. Fini, J.D. Bartlett, M. Matsubara, W.B. Rinehart, M.K.
Mody, M.T. Girard, M. Rainville, The rabbit gene for
92-kDa matrix metalloproteinase. Role of AP1 and AP2 in
 .cell type-specific transcription, J. Biol. Chem. 269 1994
28620–28628.
w x27 G.J. Darlington, D.R. Wilson, L.B. Lachman, Monocyte-
conditioned medium, interleukin-1, and tumor necrosis fac-
tor stimulate the acute phase response in human hepatoma
 .cells in vitro, J. Cell Biol. 103 1986 787–793.
w x28 J.G. Giri, R. Robb, W.L. Wong, R. Horuk, HepG2 cells
predominately express the type II interleukin 1 receptor
biochemical and molecular characterization of the IL-1
 .receptor, Cytokine 4 1992 18–23.
w x29 G.W. Varilek, G.A. Neil, W.P. Bishop, Caco-2 cells express
type I interleukin-1 receptors: ligand binding enhances pro-
 .liferation, Am. J. Physiol. G 1101 1994 1107.
w x30 A.M. Healy, T.D. Gelehrter, Induction of plasminogen acti-
vator inhibitor-1 in HepG2 human hepatoma cells by media-
 .tors of the acute phase response, J. Biol. Chem. 269 1994
19095–19100.
w x31 G.F. Paciotti, L. Tamarkin, Interleukin-1 directly regulates
( )G. Bosko˝ic, S.S. TwiningrBiochimica et Biophysica Acta 1403 1998 37–46ˇ ´46
hormone-dependent human breast cancer cell proliferation
 .in vitro, Mol. Endocrinol. 2 1988 459–464.
w x32 V. Costantini, C. Vinci, R. Mineo, F. Frasca, G. Pandini, G.
Milazzo, R. Vigneri, A. Belfoiore, Interleukin-1 blocks in-
sulin and insulin-like growth factor-stimulated growth in
MCF-7 human breast cancer cells by inhibiting receptor
 .tyrosine kinase activity, Endocrinology 137 1996 4107–
4110.
w x33 H. Ohashi, T. Maeda, H. Mishima, T. Otori, T. Nishida, T.
Sekiguchi, Upregulation of integrin a5b 1 expression by
interleukin-6 in rabbit corneal epithelial cells, Exp. Cell Res.
 .218 1995 418–423.
w x34 S.E. Wilson, G.S. Schultz, N. Chegini, J. Weng, Y.G. He,
Epidermal growth factor, transforming growth factor a ,
transforming growth factor b , acidic fibroblast growth fac-
tor, basic fibroblast growth factor and interleukin-1 proteins
 .in the cornea, Exp. Eye Res. 59 1994 63–71.
w x35 C.P. Burren, J.L. Berka, S.R. Edmondson, G.A. Werther,
J.A. Batch, Localization of mRNAs for insulin-like growth
 .factor-I IGF-I , IGF-1 receptor, and IGF binding proteins in
 .rat eye, Invest. Ophthalmol. Vis. Sci. 37 1996 1459–1468.
w x36 H. Ghiasi, S.L. Wechsler, R. Kaiwar, A.B. Nesburn, F.M.
Hofman, Local expression of tumor necrosis factor a and
interleukin-2 correlates with protection against corneal scar-
ring after ocular challenge of vaccinated mice with herpes
 .simplex virus type I, J. Virol. 69 1995 334–340.
w x37 D.T. Rieck, P. Rieck, P. Renard, C. Hartmann, Y. Courtois,
Y. Pouliquen, Corneal wound healing modulation using
basic fibroblast growth factor after excimer laser photore-
 .fractive keratectomy, Cornea 14 1995 224–234.
w x38 V.P. Hoppenreijs, E. Pels, G.F. Vrensen, W.F. Treffers,
Basic fibroblast growth factor stimulates corneal endothelial
cell growth and endothelial wound healing of human corneas,
 .Invest. Ophthalmol. Vis. Sci. 35 1994 931–944.
w x39 H.E. Boisjoly, C. LaPlante, S.F. Bernatchez, C. Salesse, M.
Giasson, M.-C. Joly, Effects of EGF, IL-1 and their combi-
nation on in vitro corneal epithelial wound closure and cell
 .chemotaxis, Exp. Eye Res. 57 1993 293–301.
w x40 F. Cozzolino, M. Torcia, M. Lucibello, L. Morbidelli, M.
Ziche, J. Platt, S. Fabiani, J. Brett, D. Stern, Interferon-al-
pha and interleukin 2 synergistically enhance basic fibrob-
last growth factor synthesis and induce release, promoting
 .endothelial cell growth, J. Clin. Invest. 91 1993 2504–
2512.
